The Center for Biosimilars writes about IVI’s recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized control trial (RCT) evidence, and updated cost estimates.
Read the full article here.
